Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

OBJECTIVE: To compare the effects of monotherapy using nateglinide and the thiazolidinedione troglitazone with initial combination of the two agents on glycated hemoglobin (HbA(1c)) in patients with type 2 diabetes inadequately controlled by diet alone. RESEARCH DESIGN AND METHODS: This study consisted of a 28-week, double-blind, randomized, multicenter study that included a 4-week, single-blind, placebo, run-in period and a 24-week (shortened to 16 weeks), double-blind, active treatment period. RESULTS: At the 16-week end point, nateglinide 120 mg, troglitazone 600 mg, and the combination of the agents achieved statistically significant decreases in HbA(1c) in comparison with placebo and a baseline HbA(1c) of 8.1-8.4% (P < 0.001). The reductions in HbA(1c) were similar in the nateglinide (0.6%) and troglitazone (0.8%) monotherapy groups. The reduction in HbA(1c) (1.7%) was greatest in the combination group; 79% of patients in the combination group achieved HbA(1c) levels of <7%. The combination group had a higher number of adverse events, primarily due to an increased incidence of mild hypoglycemia in this treatment group. CONCLUSIONS: Nateglinide and troglitazone are equally effective in decreasing HbA(1c) levels. However, these reductions from baseline HbA(1c) values of >8% are not adequate to achieve HbA(1c) levels of <7%. In contrast, the combination of nateglinide and of a thiazolidinedione shows an additive effect that is highly effective in reducing HbA(1c) levels to the target of <7% in 66% of patients, from a baseline HbA(1c) that is just above 8%.